Actively Recruiting
Evaluating Dupilumab in COPD Participants Using Real-World Data The STRIDE Registry Study of COPD Patients Treated With Dupilumab
Led by Sanofi · Updated on 2026-10-15
350
Participants Needed
7
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the real-world effects and safety of dupilumab in people with chronic obstructive pulmonary disease COPD. The study aims to describe the characteristics of participants newly starting dupilumab for COPD and compare them with COPD patients not treated with dupilumab. The research will also look at whether dupilumab reduces moderate or severe COPD flare-ups, improves lung function, enhances quality of life, and monitor safety in these participants. The study will enroll 350 COPD participants newly prescribed dupilumab over about 12 months at around 20 US sites, alongside a control group of 700 COPD participants not receiving dupilumab from an external registry. Data collected will include chest images and home spirometry measurements. Participants will receive usual care as decided by themselves and their healthcare providers. Participants will be followed and monitored for approximately 2 years, during which chest images, lung function tests, and quality of life assessments will be gathered. Researchers will evaluate participant characteristics at the end of the study and track COPD exacerbations, lung function changes, and safety events. The study involves no assigned treatments, and participants continue their regular medical care throughout the observation period.
CONDITIONS
Brief Title
The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
Research Team
T
Trial Transparency Trial Transparency
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here